Sanofi-Aventis wins rights to Taiho cancer drug
S-1 is an oral pyrimidine fluoride-derived anticancer agent in which a prodrug of 5-FluoroUracil (5-FU), Tegafur, is combined with two inhibitors of enzymes to increase the amount of
S-1 is an oral pyrimidine fluoride-derived anticancer agent in which a prodrug of 5-FluoroUracil (5-FU), Tegafur, is combined with two inhibitors of enzymes to increase the amount of
The study, conducted by researchers from Group Health Center for Health Studies, found that an obese person is about 25% more likely than a non-obese person to have
Traditional treatment for hemophilia A requires infusion of synthetic FVIII, a blood clotting protein, two to three times a week to control bleeding episodes. However, about 30% of
Although around half of pediatricians recommend that children under age two can be given diphenhydramine to help them sleep, the first study to look at effectiveness of the
The panel’s positive opinion concerns the use of Keppra (levetiracetam) as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patients from 16
Certain types of skin cancers and blindness due to age-related macular degeneration (AMD) and diabetic retinopathy are likely to be among the first uses for the drug. The
Results from Dendreon’s pivotal phase III study (D9901) of Provenge (sipuleucel-T) were published in the Journal of Clinical Oncology. The double-blind, placebo-controlled study showed that the group of
Lucentis was specifically developed for intraocular use in the eye to treat the underlying cause of ‘wet’ age-related macular degeneration (AMD) by targeting the molecular pathway that controls
In a large, population-based study comparing risk factors in people with and without colorectal cancer, the researchers found the highest risk of colon cancer to be among long-term
The study was carried out by researchers from the Johns Hopkins Bloomberg School of Public Health and the Johns Hopkins University School of Medicine. It determined that, in